(Reuters) -Mikael Dolsten, Pfizer's former research and development chief, has withdrawn his candidacy for Novo Nordisk's board, citing personal reasons, the Danish drugmaker said on Thursday. Dolsten ...
Lars Rebien Sorensen is back as chairman of Novo Nordisk A/S following a shareholder meeting that exposed the depth of rivalry between the Danish drugmaker and US arch nemesis Pfizer Inc. The ...
Pfizer's weight management pipeline just got a boost.
Connecticut-based Pfizer Inc. said Thursday that it has completed the successful acquisition of Metsera, Inc., which is “a clinical-stage biopharmaceutical company accelerating the next generation of ...
Nov 13 (Reuters) - Mikael Dolsten, Pfizer's (PFE.N), opens new tab former research and development chief, has withdrawn his candidacy for Novo Nordisk's (NOVOb.CO), opens new tab board, citing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback